

TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY THE MERCHANT BANKER IN THE LAST 3 FINANCIAL YEARS



Name of the issuer :

Influx Healthtech Limited

1	Type of issue (IPO/ FPO)	SME IPO
2	Issue size (Rs crore)	Rs. 58.57 Crs <i>Fresh - Rs. 48.01 crs</i> <i>OFS - Rs. 10.56 crs</i>
3	Grade of issue alongwith name of the rating agency	Not applicable
4	Subscription level (number of times)	201.35 times.
5	QIB holding (as a % of total outstanding capital) as disclosed to stock exchanges	
	(i) allotment in the issue	5.00%
	(ii) at the end of the 1st Quarter immediately after the listing of the issue	8.67%
	(iii) at the end of FY 2025-26	5.81%
	(iv) at the end of FY 2026-27	Not applicable
	(v) at the end of FY 2027-28	Not applicable

6 Financials of the issuer (as per the annual financial results submitted to stock exchanges)

Standalone Basis		(Rs. in lakhs)	
Parameters	FY 2025-26	FY 2026-27	FY 2027-28
Income from operations	14,816.85	Not applicable	Not applicable
Net Profit for the period	2,054.13	Not applicable	Not applicable
Paid-up equity share capital	2,315.04	Not applicable	Not applicable
Reserves excluding revaluation reserves	Not applicable	Not applicable	Not applicable

7 Trading status in the scrip of the issuer (whether frequently traded (as defined under Regulation 2 (j) of SEBI (SAST) Regulations, 2011) or infrequently traded/ delisted/ suspended by any stock exchange, etc.)

(i) at the end of FY 2025-26	Frequently traded
(ii) at the end of FY 2026-27	Not applicable
(iii) at the end of FY 2027-28	Not applicable

8 Change, if any, in directors of issuer from the disclosures in the offer document

(i) at the end of FY 2025-26	Mr Ashok Kumar Jain	Resignation
	Mr Mohmad Saleh Mutvalli	Appointment
(ii) at the end of FY 2026-27	Not applicable	
(iii) at the end of FY 2027-28	Not applicable	

9 Status of implementation of project/ commencement of commercial production (as submitted to stock exchanges under Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Reg, 2015

(i) as disclosed in the offer document	Under Process*
(ii) Actual implementation	Under Process*
(iii) Reasons for delay in implementation, if any	Not applicable
*The company still have time to implement the project as dislcoused in offer documents.	

10 Status of utilization of issue proceeds (as submitted to stock exchanges under Regulation 32 of the SEBI (Listing Obligations & Disclosure Requirements) Regulation, 2015

Rs. In crs			
Objects as disclosed in the Offer document	Amount disclosed in the Offer document	Actual Utilized Amount upto 31-Mar-2026	Unutilized Amount as on 31-Mar-2026*

TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY THE MERCHANT BANKER IN THE LAST 3 FINANCIAL YEARS

<i>Funding Capital expenditure requirements for setting up of manufacturing facilities</i>	36.73	13.13	23.60
<i>General Corporate Purpose</i>	6.67	6.67	0
<i>Public Issue Expenses</i>	5.83	5.83	0

**The company is in process to utilize the IPO proceeds*

11 *Comments of monitoring agency, if applicable* *Not applicable*

12 *Price- related data*

Issue price (Rs): **Rs. 96 /-**

<i>Price parameters</i>	<i>At close of listing day i.e., 25-Jun-2025</i>	<i>At close of 30th calendar day from listing day i.e., 24-Jul-2025</i>	<i>At close of 90th calendar day from listing day i.e., 24-Sep-2025</i>	<i>As at the end of FY 2025-26</i>			<i>As at the end of FY 2026-27</i>			<i>As at the end of FY 2027-28</i>		
				<i>Closing price</i>	<i>High</i>	<i>Low</i>	<i>Closing price</i>	<i>High</i>	<i>Low</i>	<i>Closing price</i>	<i>High</i>	<i>Low</i>
<i>Market Price</i>	Rs. 126.20 /-	Rs. 151.20 /-	Rs. 185.10 /-	214.55	219.8	200	NA	NA	NA	NA	NA	NA
<i>Index (of the Designated Stock Exchange): NSE SME Emerge</i>	Rs. 14,656.55 /-	Rs. 15,150.54 /-	Rs. 15,545.42 /-	12,500.05	12,685.40	12,392.15	NA	NA	NA	NA	NA	NA
<i>Sectoral Index (mention the index that has been considered and reasons for considering the same)</i>	Not comparable to any of the available sectoral indices			NA	NA	NA	NA	NA	NA	NA	NA	NA

NA - Not applicable

13 *Basis for Issue Price and Comparison with Peer Group & Industry Average* (Source of accounting ratios of peer group and industry average may be indicated; source of the accounting ratios may generally be the same, however in case of different sources, reasons for the same may be indicated)

Accounting ratio	Name of company	<i>As disclosed in the offer document (See Clause (2) (VII) (K) of Schedule VIII to SEBI (ICDR) Reg, 2018</i>	<i>As at the end of FY 2025-26</i>	<i>As at the end of FY 2026-27</i>	<i>As at the end of FY 2027-28</i>
EPS	Issuer:	7.36	9.35	NA	NA
	Peer Group:Sudarshan Pharma Industries Ltd	0.66	0.91	NA	NA
	Peer Group:Quest Laboratories ltd	8.28	9.2	NA	NA
P/E	Issuer:	13.04	32.58	NA	NA
	Peer Group:Sudarshan Pharma Industries Ltd	48.28	25	NA	NA
	Peer Group:Quest Laboratories ltd	10.38	9.96	NA	NA
RoNW	Issuer:	36.98%	20%	NA	NA
	Peer Group:Sudarshan Pharma Industries Ltd	12.45%	16.30%	NA	NA
	Peer Group:Quest Laboratories ltd	16.58%	16.80%	NA	NA
NAV per share based on balance sheet	Issuer:	19.91	43.52	NA	NA
	Peer Group:Sudarshan Pharma Industries Ltd	5.3	6.44	NA	NA
	Peer Group:Quest Laboratories ltd	49.92	59.08	NA	NA

TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY THE MERCHANT BANKER IN THE LAST 3 FINANCIAL YEARS

14 *Any other material information* Nil